Founded in St. Louis by an experienced team of pharmaceutical and biotech veterans, Galera will use the proceeds to advance clinical development of its promising new drug candidate, which has earned “Breakthrough Therapy” designation by the FDA for its promising ability to reduce the incidence and duration of severe oral mucositis, a side effect of radiation treatment in head and neck cancer patients.
Search
Galera Therapeutics
